New Drug Sponsors Should Not Contact US FDA Reviewers Directly, Draft Guidance Asserts
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is urging investigational new drug application sponsors to communicate directly with review division regulatory project managers instead of contacting project managers and reviewers.